Compare Neurocrine Biosciences Inc (NBIX) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs TeraWulf Inc — how do they compare? Neurocrine Biosciences Inc trades at $142.25 (market cap $14.36B), while TeraWulf Inc trades at $13.7 (market cap $6.81B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.1× TeraWulf Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, TeraWulf Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and TeraWulf Inc for 17 Days on average.
| NBIX | WULF | |
|---|---|---|
Market Cap | $14.36B | $6.81B |
Volume | 1,237,180 | 45,841,998 |
Sector | Health | Financials |
52-Week High | $185.50 | $28.98 |
52-Week Low | $123.10 | $10.99 |
Typical Hold Time | 23 Days | 17 Days |
Enterprise Value | $14.37B | $9.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
TeraWulf (WULF) trades at $13.73, down 4.65% today, amid bearish technical signals despite unanimous analyst optimism. The stock shows severe fundamental strain with negative profit margins (-1,179.94% net income margin) and consecutive earnings misses, though revenue remains stable near $168M. Recent news highlights the company's pivot to AI data center operations, with UBS initiating bullish coverage citing long-term power access advantages.
While analyst consensus points to significant upside (average target $34.92), the stock faces substantial execution risks in its AI transition amid persistent cash burn. Investors must weigh Wall Street's optimistic price targets against the company's current negative profitability and high valuation multiples in a competitive infrastructure sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
